CORONA, Calif., March 27, 2017 -- Executives of Acology Inc. (OTC:ACOL), in response to investor inquiries about the company’s multinational expansion, have expressed confidence that the anticipated legalization of recreational cannabis in Canada will produce growth and strong, sustained retail and wholesale business.
With the Canadian National Government, led by strong, pro-cannabist Prime Minister Justin Trudeau, ready to ask for legalization in the next few weeks and the high likelihood of the referendum passing, companies that have anticipated legalization are in a good position to benefit from the new law.
The investment in Canadian expansion, where Acology has had a business operations since 2013, began in the last quarter of calendar 2016 and has already begun to produce steady increases in sales in the first quarter of 2017. Recent high-level meetings with other Canadian cannabis firms and potential distributors have continued amid the growing confidence in the expanding market.
The Canadian market potential has been estimated at $10B in the first full year. Distribution points for both medical and recreational cannabis, serving what will be a rapidly-expanding consumer market, have been the focus of much of Acology’s expansion effort. There is growing confidence that these expansion points will provide the market increase that they have been preparing for.
For investor or sales information please visit Acology Inc. and D&C Distributors online or by phone. The company is located in their production and distribution facility at 1620 Commerce St. Corona, California, 92880.
Acology trades on the OTC under the call letters ACOL. The company’s websites are www.Acologyinc.com for the hospice and palliative care industry and www.themedtainer.com for the recreational and medical marijuana industry. Orders for Acology products can be taken online and by phone. Custom orders are especially welcome. Please send all inquiries to [email protected] or call (844) ACOLOGY (844-226-5649). Ask for Jack Rein, National Services Director. Acology can also be accessed through Twitter and Instagram at @Acologyinc.
This press release includes statements that are covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events they are subject to risks and uncertainties and actual results for fiscal year 2016 and beyond could differ materially from the company’s current expectations. Forward-looking statements are identified by such words as “anticipates”, “projects”, “expects”, “planned”, “intends” and “believes” “estimate” “targets” and other similar expressions that indicate trends and future events. It is understood that investment entails risk on the part of the investor and could result in the loss of some or all his or her investment.


AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability
Starlink Internet Remains Active in Iran Despite Nationwide Blackout
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable”
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 



